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Abstract
The fundamental principle in regulatory toxicology is that all chemicals are toxic and that the severity of effect is
proportional to the exposure level. An ancillary assumption is that there are no effects at exposures below the lowest
observed adverse effect level (LOAEL), either because no effects exist or because they are not statistically resolvable,
implying that they would not be adverse. Chemicals that interfere with hormones violate these principles in two
important ways: dose–response relationships can be non-monotonic, which have been reported in hundreds of studies
of endocrine disrupting chemicals (EDCs); and effects are often observed below the LOAEL, including all environmental
epidemiological studies examining EDCs. In recognition of the importance of this issue, Lagarde et al. have published
the first proposal to qualitatively assess non-monotonic dose response (NMDR) relationships for use in risk assessments.
Their proposal represents a significant step forward in the evaluation of complex datasets for use in risk assessments.
Here, we comment on three elements of the Lagarde proposal that we feel need to be assessed more critically and
present our arguments: 1) the use of Klimisch scores to evaluate study quality, 2) the concept of evaluating study
quality without topical experts’ knowledge and opinions, and 3) the requirement of establishing the biological
plausibility of an NMDR before consideration for use in risk assessment. We present evidence-based logical arguments
that 1) the use of the Klimisch score should be abandoned for assessing study quality; 2) evaluating study quality
requires experts in the specific field; and 3) an understanding of mechanisms should not be required to accept
observable, statistically valid phenomena. It is our hope to contribute to the important and ongoing debate about
the impact of NMDRs on risk assessment with positive suggestions.
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Background
Paracelsus, considered the father of modern toxicology,
stated, “All things are poison and nothing (is) without
poison. Solely the dose determines that a thing is not a
poison” [1]. This central dogma in toxicology is often re-
stated as “the dose makes the poison”, which is not
exactly the same, and has been taken to mean that the
adverse effect of a toxin is proportional to the dose. The
further assumption of a monotonic, if not linear, rela-
tionship between dose and effect is used as the founda-
tion for modern risk assessments, where the effects of
high doses are used to predict effects – and lack of
effects – at lower doses.
In contrast, a group of independent scientists pub-
lished in 2012 the first comprehensive review of the
endocrine disrupting chemical (EDC) literature that re-
vealed a large number of non-monotonic dose responses
(NMDRs) in biochemical, animal and human studies [2].
The large number of NMDRs assessed led several
groups to conclude that these dose responses are com-
mon for both hormones and EDCs [3-6]. Although
non-monotonicity has received significant attention in
the last few years, these phenomena are not new and
their importance to risk assessment has been consid-
ered previously [7].
The 2012 literature review also spawned an intense
debate about the reality of NMDRs and their importance
for risk assessments (e.g., [8-11]). Some authors argued
that because NMDRs are common for hormones, and
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for drugs that interact with hormone receptors, it is
reasonable to predict that environmental chemicals that
interact with hormone system would also exhibit
NMDRs [2-4,6,12,13]. However, others argued that the
data were insufficient to conclude that NMDRs are real
or important (e.g., [10]). In general, this kind of debate is
healthy and can provide the driving force for new sci-
ence and new analyses. However, debate surrounding a
controversy often paralyzes the risk assessment process.
Therefore, a proposal to assess NMDRs using systematic
criteria is important to bring this debate within the risk
assessment domain.
A new systematic approach to assess NMDRs
Considering the scientific climate and desire to develop
approaches for the assessment of NMDRs, Lagarde et al.
(2015) [14] published the first formal strategy for consid-
ering the use of datasets with NMDRs for inclusion in
risk assessment. They propose a five step decision tree
for the evaluation of NMDRs for their use in risk assess-
ments: 1) The assessment of study quality; 2) determin-
ation of number of doses; 3) characterization of data for
specific statistical analyses; 4) statistical analysis using de-
fined criteria; and 5) assessment of biological plausibility.
The contribution made by Lagarde and colleagues is a
significant advancement for the field of risk assessment,
which was built on the expectation of monotonic dose
responses. In this way, the Lagarde decision tree pro-
vides the first contribution by which NMDRs could be
assessed and then used to identify ‘safe’ levels of chem-
ical exposures.
However, from the perspective of basic science, we
would like to address three elements of this decision
tree: 1) the use of Klimisch scores to evaluate study
quality, 2) the concept of evaluating study quality with-
out topical experts’ opinions, and 3) the requirement of
establishing the biological plausibility of an NMDR be-
fore consideration for use in risk assessment.
Klimisch scores
The first step in the Lagarde decision tree characterizes
the quality of the study under consideration. The assess-
ment of study quality is a standard step in the risk assess-
ment process. In the study of EDCs, endocrinologists and
environmental health scientists have proposed a series of
criteria that should be met to consider a study “high qual-
ity” including the use of appropriate negative and positive
controls, the use of sensitive animal species and strains,
and the use of appropriate endpoints [3,15-18]. All of
these criteria specifically focus on aspects of study design
and are derived from an understanding of endocrine sys-
tems and their role in development and physiological con-
trol. In contrast, Klimisch et al. [19] propose a system for
evaluating the quality of a scientific study based on its
adherence to test guidelines and study reporting criteria
including the employment of Good Laboratory Practices
(GLP). Using the Klimisch scoring system, studies given
the highest ranking (“Reliable without Restriction”) are
those “…studies or data from the literature or reports
[presumably not published in the peer review literature]
which were carried out or generated according to gener-
ally valid and/or internationally accepted testing guidelines
(preferably performed according to GLP) or in which the
test parameters documented are based on a specific (na-
tional) testing guideline (preferably performed according
to GLP) or in which all parameters described are closely
related/comparable to a guideline method.” [19]. Import-
antly, as noted elsewhere, GLP criteria are typically only
followed by industry-funded or government laboratories
as these high-cost, personnel-intensive standards were de-
veloped in response to several examples of fraud commit-
ted in industry labs [20-22]; thus, the Klimisch score is an
industry-developed method which typically gives the high-
est quality rankings to industry-funded studies [23].
Unfortunately, the Klimisch scoring system confounds
quality in study design and execution (which are directly
related to quality in the resulting data) with quality in
recordkeeping and study reporting. For example, GLP
compliant studies do not prevent test substance contam-
ination of the untreated control group [24], or guarantee
that the positive control group has responded as ex-
pected [17], or that the tissues being studied have been
dissected appropriately [21]. Other groups have similarly
noted that the conflation of quality of reporting and
quality of data is problematic [25].
There are also significant weaknesses in guideline
studies as they relate to EDCs – whether or not they are
performed according to GLP [4,20]. For example, most
guideline studies only examine three treatment doses,
which is not sufficient to make a conclusive judgment
about the shape of the dose response curve. Similarly,
guideline studies can be performed on animal species
and strains that are insensitive to hormones, and thus
are not appropriately responsive to EDCs at low doses
[26]. Moreover, the endpoints assessed in traditional
guideline studies do not address the most important
chronic diseases in human populations today (e.g., [17])
and therefore will limit the utility of the overall risk
assessment process. Unfortunately, the use of Klimisch
scores will restrict the endpoints considered “adverse” to
those endpoints captured by traditional guideline stud-
ies. Thus, while a focus on study quality is a positive
aspect of the Lagarde proposal, the reliance on Klimisch
scores is a major weakness.
Use of topical experts
Klimisch scores are more of a bureaucratic strategy than
a scientific one, and provide a rationale allowing for
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non-experts to evaluate study quality with confidence,
even when they do not understand the underlying biol-
ogy of the study at hand. The engagement of topical ex-
perts would clearly produce difficult challenges, in part
because the examples of NMDRs in EDC studies occur
at many levels of investigation (e.g., in vitro, animal
study, human study), on many different hormone sys-
tems (of which there are 10 or so that are evaluated as
targets of chemical actions), and at multiple life cycle
stages. The complexity of these issues should not be
underestimated. As an example from our experience,
thyroid hormone has very specific effects during brain
development (i.e. processes that occur in utero and the
early postnatal period). In rodent studies of brain devel-
opment, thyroid hormone regulates the expression of
different genes through different receptors, in a temporally
and spatially specific manner. Studies in genetic strains of
mice have revealed which isoform of thyroid hormone
receptor is responsible for certain features of thyroid
hormone action on brain development [27]. Likewise,
painstaking studies over development demonstrate that
a single gene (e.g., RC3) is regulated by thyroid hor-
mone in some – but not all – regions of the brain, and
at some – but not all – times during development [28].
The complexity of the thyroid system and methods for
studying it led to the development of an 81-page docu-
ment by the American Thyroid Association [29] to guide
investigators in this domain and improve the overall
quality of research in this area. This complexity obvi-
ously extends to other hormones, physiological pro-
cesses and organisms, including humans. Therefore, to
evaluate the quality of a study designed to inform us
about the ability of a manufactured chemical to interfere
with hormone action, experts in the hormone system
and physiological events under study must be recruited
to contribute to this essential exercise. The Lagarde
et al. method [14] does not specifically address the im-
portance of specialists in the endpoint of interest when
risk assessments are being conducted, but their use of
the Klimisch score should again be reconsidered for this
reason. It is also important to recognize that the strategy
of Klimisch et al. is to improve the overall quality of the
science being considered in a regulatory decision by ex-
cluding studies about which there is some question. We
propose that an alternate strategy would improve risk
assessment in general: to identify the strength of each
study – as well as their limitations – and determine the
role of that information in hazard identification and
characterization. This will require specialists.
Biological plausibility of NMDRs
The Lagarde et al. proposal first includes a rigorous
evaluation of the statistical validity of the NMDR under
study. This strategy will eliminate simple outliers in
datasets, or when the dataset does not include enough
dose levels to reasonably determine the shape (mono-
tonicity versus non-monotonicity) of the dose–response
relationship. This is an important issue because datasets
can be quite complex and even guideline studies can be
filled with random fluctuations. However, the second
phase focuses on evaluating the biological plausibility of
the dose response relationship. That is, what is the
mechanism that produces this dose–response curve?
There are two weaknesses with this concept. First, un-
derstanding mechanisms that link specific chemical ex-
posures to specific outcomes is highly complex and time
consuming, even though several general mechanisms by
which NMDRs can be produced are known (e.g.
[16,30-32]). In many cases, understanding the mechan-
ism underlying a dose–response shape could take years,
or decades, after the discovery of a biological
phenomenon. For example, the mechanism (s) by which
polychlorinated biphenyls (PCBs) produce neurotox-
icity can still be debated nearly 40 years after their pro-
duction was banned, whereas the phenomenon itself
(neurotoxicity) is widely acknowledged [33,34]. More-
over, non-specialists will make the judgment regarding
biological plausibility of a dose response, providing an
enormous opening for variability in the application of
this decision tree, and one potentially driven by agendas.
Second, the fact that this mechanistic determination is
being required of a chemical exhibiting an NMDR with
some health outcome is in contrast to chemicals that pro-
duce a monotonic dose–response. Monotonic dose re-
sponse phenomena are accepted as the default in risk
assessments, even when the mechanism is not under-
stood. Thus, there is an inherent asymmetry in the ana-
lysis, which reveals a fundamental bias in the approach. In
this way, the Lagarde decision tree creates a situation
where it is possible for a statistically valid NMDR con-
cerning important adverse effects to be ignored if a risk
assessor “feels” that the biological mechanism for the
observed non-monotonicity is not sufficiently well under-
stood. These issues should be addressed before it is used
in the risk assessment process. Specifically, mechanisms
should not be required to accept biological observations
or phenomena in the risk assessment process, and non-
monotonic and monotonic dose responses should be
treated equally in these assessments.
Conclusions
The “risk-based approach” to chemical safety is balanced
on the principle that all chemicals are toxic, that ‘the
dose makes the poison’, and that there are no adverse
effects below the calculated “safe” level. If, and only if,
these principles are true, the human population can be
safely exposed to hundreds of toxic chemicals simultan-
eously as long as the exposure to each one is below the
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level calculated with these assumptions. The risk assess-
ment process in general has been challenged for EDCs,
and one part of this challenge is the inability of this risk-
based approach to adapt to NMDRs, which are common
for this class of chemicals. Recently, several academic
and government groups have developed methods to im-
prove the processes of systematic review [25,35,36]. The
Lagarde decision tree provides methods by which
NMDRs can be assessed and included in a risk assess-
ment. This is important because dose response data are
combined with hazard assessment and exposure data in
the risk characterization process; if a non-monotonic
relationship is apparent between chemical dose and an
adverse outcome, extrapolation from high doses that are
‘toxic’ to lower doses, presumed to be safe, should not
be done [2,3]. We have reviewed three areas in which
the Lagarde decision tree should be improved. With
these relatively minor, but very important amendments,
this decision tree could offer vast progress for the risk
assessment community.
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